The University of Southampton
University of Southampton Institutional Repository

The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria.

Staevska, Maria, Popov, Todor A., Kralimarkova, Tanya, Lazarova, Cvetelina, Kraeva, Steliana, Popova, Dora, Church, Diana S., Dimitrov, Vasil and Church, Martin K. (2010) The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. Journal of Allergy and Clinical Immunology, 125, (3), pp. 676-682. (doi:10.1016/j.jaci.2009.11.047).

Record type: Article

Abstract

Background H1-antihistamines are first line treatment of chronic urticaria, but many patients do not get satisfactory relief with recommended doses. European guidelines recommend increased antihistamine doses of up to 4-fold.
Objective To provide supportive evidence for the European guidelines.
Methods Eighty tertiary referral patients with chronic urticaria (age range, 19-67 years) were randomized for double-blind treatment with levocetirizine or desloratadine (40/40). Treatment started at the conventional daily dose of 5 mg and then increased weekly to 10 mg, 20 mg, or 20 mg of the opposite drug if relief of symptoms was incomplete. Wheal and pruritus scores, quality of life, patient discomfort, somnolence, and safety were assessed.
Results Thirteen patients became symptom-free at 5 mg (9 levocetirizine vs 4 desloratadine), compared with 28 subjects on the higher doses of 10 mg (8/7) and 20 mg (5/1). Of the 28 patients nonresponsive to 20 mg desloratadine, 7 became symptom-free with 20 mg levocetirizine. None of the 18 levocetirizine nonresponders benefited with 20 mg desloratadine. Increasing antihistamine doses improved quality of life but did not increase somnolence. Analysis of the effect of treatment on discomfort caused by urticaria showed great individual heterogeneity of antihistamine responsiveness: 15% of patients were good responders, 10% were nonresponders, and 75% were responders to higher than conventional antihistamine doses. No serious or severe adverse effects warranting discontinuation of treatment occurred with either drug.
Conclusion Increasing the dosage of levocetirizine and desloratadine up to 4-fold improves chronic urticaria symptoms without compromising safety in approximately three quarters of patients with difficult-to-treat chronic urticaria.

Full text not available from this repository.

More information

Published date: March 2010
Keywords: urticaria, levocetirizine, antihistamines, desloratadine, somnolence, quality of life
Organisations: Infection Inflammation & Immunity

Identifiers

Local EPrints ID: 79608
URI: http://eprints.soton.ac.uk/id/eprint/79608
ISSN: 0091-6749
PURE UUID: 927c0369-a457-482e-b577-51765e556e8b

Catalogue record

Date deposited: 17 Mar 2010
Last modified: 18 Jul 2017 23:17

Export record

Altmetrics

Contributors

Author: Maria Staevska
Author: Todor A. Popov
Author: Tanya Kralimarkova
Author: Cvetelina Lazarova
Author: Steliana Kraeva
Author: Dora Popova
Author: Diana S. Church
Author: Vasil Dimitrov
Author: Martin K. Church

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×